Provided by Tiger Trade Technology Pte. Ltd.

IDEAYA Biosciences

37.81
-0.6100-1.59%
Post-market: 37.810.00000.00%19:30 EDT
Volume:712.27K
Turnover:27.09M
Market Cap:3.64B
PE:-19.33
High:39.32
Open:38.34
Low:37.62
Close:38.42
52wk High:42.68
52wk Low:26.05
Shares:96.27M
Float Shares:94.37M
Volume Ratio:0.77
T/O Rate:0.75%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9561
EPS(LYR):-1.2849
ROE:-16.22%
ROA:-11.54%
PB:3.04
PE(LYR):-29.43

Loading ...

Ideaya Biosciences Shares Gain Ahead of Trial Results

Dow Jones
·
Apr 11

BRIEF-Ideaya Biosciences To Announce Topline Results From Phase 2/3 Optimum-02 Trial In Metastatic Uveal Melanoma On Monday, April 13, 2026

Reuters
·
Apr 11

IDEAYA to report topline OptimUM-02 darovasertib-crizotinib trial results April 13

Reuters
·
Apr 11

IDEAYA Biosciences to Announce Topline Results From Phase 2/3 Optimum-02 Trial in Metastatic Uveal Melanoma on Monday, April 13, 2026

THOMSON REUTERS
·
Apr 11

BUZZ-U.S. STOCKS ON THE MOVE-Amazon, Northrop Grumman, Brown-Forman

Reuters
·
Apr 10

Ideaya Biosciences Inc - Enters Clinical Collaboration Agreement With Astrazeneca On April 8, 2026 - SEC Filing

Reuters
·
Apr 09

IDEAYA, AstraZeneca partner to test IDE849 with Imfinzi in small cell lung cancer

Reuters
·
Apr 09

IDEAYA Biosciences Inc - Co to Sponsor Study; AstraZeneca to Supply Imfinzi - SEC Filing

THOMSON REUTERS
·
Apr 09

IDEAYA Biosciences Inc - Agreement to Evaluate Ide849 With Imfinzi in Extensive-Stage Small Cell Lung Cancer - SEC Filing

THOMSON REUTERS
·
Apr 09

IDEAYA Biosciences Inc - Advancing Global Phase 1 Trial for Ide849 in Dll3 Upregulated Solid Tumors - SEC Filing

THOMSON REUTERS
·
Apr 09

BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Norfolk Southern, Denali

Reuters
·
Apr 07

BUZZ-U.S. STOCKS ON THE MOVE-Tyson Foods, Atmus Filtration, Avis Budget

Reuters
·
Apr 06

BUZZ-U.S. STOCKS ON THE MOVE-Legence, Valero Energy, Stereotaxis

Reuters
·
Apr 06

BUZZ-U.S. STOCKS ON THE MOVE-Soleno Therapeutics, Ideaya Biosciences, Profusa

Reuters
·
Apr 06

Analysts Offer Insights on Healthcare Companies: Pelthos Therapeutics (PTHS), IDEAYA Biosciences (IDYA) and Viridian Therapeutics (VRDN)

TIPRANKS
·
Apr 06

BUZZ-IDEAYA Biosciences rises as early-stage cancer trial starts

Reuters
·
Apr 06

IDEAYA enrolls first patient in Phase 1 trial of KAT6/7 inhibitor IDE574

Reuters
·
Apr 06

IDEAYA Biosciences Announces First-Patient-in for Phase 1 Trial of Ide574, a Potential First-in Class Dual Inhibitor of Kat6/7 to Target Multiple Solid Tumor Indications, Including Breast, Prostate, Crc, and Lung Cancer

THOMSON REUTERS
·
Apr 06